Long‐Term Cardiovascular Risks of Anticholinergic Versus Non‐Anticholinergic Antidepressants: A Target Trial Emulation With Negative Control Correction
Pharmacoepidemiology and Drug Safety · 2026-07 · 35 (7)
DOI: 10.1002/pds.70434 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Pharmacoepidemiology and Drug Safety, online erschienen am 14.07.2026. Verfasst von Yang Xu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University, Beijing, China. Hauptthemen laut MEDLINE: Cholinergic Antagonists, Antidepressive Agents, Cardiovascular Diseases. Die Arbeit nennt 70 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China, Gates Foundation, American Diabetes Association.
Abstract (Originalsprache)
Purpose
Antidepressants remain widely prescribed worldwide, and the potential cardiovascular risks associated with their anticholinergic properties are poorly understood.
Methods
We employed an active‐comparator new‐user design to emulate a target trial spanning 2006–2021 in UK Biobank. Participants aged ≥ 40 years with linked primary care records who newly initiated an anticholinergic vs. a non‐anticholinergic antidepressant were included. The primary outcome was hospitalization or death from cardiovascular events. To adjust for measured and unmeasured confounding, we applied propensity score matching (PSM) with proximal causal inference (PCI) and negative control outcome calibration (NCOC) to estimate the intention‐to‐treat hazard difference (HD). Subgroup analyses were conducted by age, sex, socioeconomic status, lifestyle factors, apolipoprotein E genotype, and major comorbidities. Sensitivity analyses included data‐driven negative control selection, alternative anticholinergic burden scale, comparisons across different anticholinergic burden levels, complete‐case analysis, a 6‐month induction period, and a 2‐year washout period.
Results
The study included 24 547 anticholinergic antidepressant users and 20 519 non‐anticholinergic users. Measured covariates were balanced among 32 588 PS‐matched participants with a median follow‐up of 9.1 years. Negative control correction revealed anticholinergic antidepressant use was associated with increased risk of cardiovascular events (HD PSM + PCI : 59.96 per 10 000 person‐years [95% CI: 43.32, 76.60]; HD PSM + NCOC : 31.35 [17.95, 45.26]). Elevated risks were observed for ischemic stroke, acute coronary syndrome, heart failure, arrhythmias, arterial disease, and venous thromboembolism. Results were consistent across subgroup and sensitivity analyses.
Conclusions
Anticholinergic antidepressants may increase the risk of cardiovascular events compared with non‐anticholinergic antidepressants. These findings underscore prioritizing therapeutic options with a lower anticholinergic burden in clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University, Beijing, China.
- Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden.
- Department of Neurobiology, Care Sciences and Society, Karolinska Institute, Stockholm, Sweden.
- Key Laboratory of Epidemiology of Major Diseases, Ministry of Education/Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, China.
- Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
- School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.
Förderung
- National Natural Science Foundation of China
- Gates Foundation
- American Diabetes Association
- Bill and Melinda Gates Foundation
Zitieren
APA
Xu, Y., Xu, H., Guo, J., Her, Q. L., Li, R., Lai, Y., Zhang, Y., Tan, E. C. K., & Zhan, S. (2026). Long‐Term Cardiovascular Risks of Anticholinergic Versus Non‐Anticholinergic Antidepressants: A Target Trial Emulation With Negative Control Correction. Pharmacoepidemiology and Drug Safety, 35(7). https://doi.org/10.1002/pds.70434
Vancouver
Xu Y, Xu H, Guo J, Her QL, Li R, Lai Y, et al. Long‐Term Cardiovascular Risks of Anticholinergic Versus Non‐Anticholinergic Antidepressants: A Target Trial Emulation With Negative Control Correction. Pharmacoepidemiology and Drug Safety. 2026;35(7). doi:10.1002/pds.70434
BibTeX
@article{Xu2026,
author = {Xu, Yang and Xu, Hong and Guo, Jinxin and Her, Qoua Liang and Li, Ruyu and Lai, Yongjie and Zhang, Yue and Tan, Edwin C K and Zhan, Siyan},
title = {Long‐Term Cardiovascular Risks of Anticholinergic Versus Non‐Anticholinergic Antidepressants: A Target Trial Emulation With Negative Control Correction},
journal = {Pharmacoepidemiology and Drug Safety},
year = {2026},
volume = {35},
number = {7},
doi = {10.1002/pds.70434}
}
EUVIMED